<DOC>
	<DOCNO>NCT00743782</DOCNO>
	<brief_summary>This study evaluate safety , biological activity , pharmacokinetics PTH deliver subcutaneous injection compare infusion pump . We anticipate pump delivery PTH physiologic mimic normal parathyroid gland secretion PTH . We expect pump delivery simultaneously normalize blood urine calcium , phosphorus magnesium level minimal fluctuation throughout day . Pump therapy require low PTH dos normalize marker bone turnover . We expect improve metabolic control pump therapy especially evident patient severe form hypoparathyrodism unmet need improve therapy .</brief_summary>
	<brief_title>Comparing Pump With Subcutaneous Injection Delivery PTH 1-34 Management Chronic Hypoparathyroidism</brief_title>
	<detailed_description>Prior study ( 92-CH-0011 ) important establish synthetic human parathyroid hormone 1-34 ( PTH ) beneficial treatment hypoparathyroidism , superior conventional therapy calcium calcitriol . We conduct randomize crossover study compare twice-daily subcutaneous injection vs. PTH pump therapy . We hypothesize pump delivery PTH 1-34 , compare twice-daily administration , provide smooth metabolic control serum mineral level normalization urine mineral excretion . The two arm divide inpatient outpatient phase . There three inpatient admission , baseline , 3 month , 6 month . Subjects randomize either pump therapy twice daily injection begin study cross alternate PTH delivery system ( injection vs. pump ) conclusion initial 3-month treatment period . Patients 10 70 year age chronic hypoparathyroidism least 1 year may eligible study . Participants two 10- 12-day hospital admission one 5-day admission . The first two inpatient admission separate 3-month outpatient period . Outpatient monitoring require weekly blood test monthly urine test monitor mineral level . After third hospital admission , patient place conventional therapy .</detailed_description>
	<mesh_term>Hypoparathyroidism</mesh_term>
	<mesh_term>Hypocalcemia</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>INCLUSION CRITERIA : This study include patient gender ( age 770 ) biochemically confirm chronic hypoparathyroidism least one year duration . Twentyfour subject enrol . EXCLUSION CRITERIA : Subjects meet follow criterion eligible study : Pregnancy Patients calcium infusion dependent and/or respond calcitriol therapy maintain normal level serum calcium exclude . Seizure disorder require antiepileptic medication .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 7, 2014</verification_date>
	<keyword>Hypoparathyroidism</keyword>
	<keyword>Parathyroid Hormone 1-34</keyword>
</DOC>